Which has preferable earnings & valuation, ACRV or AKTX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acrivon Therapeutics N/A N/A -$77.90M -$1.88 N/A Akari Therapeutics N/A N/A -$17.30M N/A N/A

Is ACRV or AKTX more profitable?

Acrivon Therapeutics' return on equity of -70.14% beat Akari Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Acrivon Therapeutics N/A -70.14% -61.60% Akari Therapeutics N/A -147.45% -74.70%

Does the media prefer ACRV or AKTX?

In the previous week, Acrivon Therapeutics had 6 more articles in the media than Akari Therapeutics. MarketBeat recorded 8 mentions for Acrivon Therapeutics and 2 mentions for Akari Therapeutics. Akari Therapeutics' average media sentiment score of 0.61 beat Acrivon Therapeutics' score of 0.26 indicating that Akari Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acrivon Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Akari Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, AKTX or TELO?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Akari Therapeutics N/A N/A -$17.30M N/A N/A Telomir Pharmaceuticals N/A N/A -$10.41M -$0.89 N/A

Is AKTX or TELO more profitable?

Telomir Pharmaceuticals' return on equity of -107.89% beat Akari Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Akari Therapeutics N/A -147.45% -74.70% Telomir Pharmaceuticals N/A -107.89% -94.72%

Does the media favor AKTX or TELO?

In the previous week, Telomir Pharmaceuticals had 1 more articles in the media than Akari Therapeutics. MarketBeat recorded 3 mentions for Telomir Pharmaceuticals and 2 mentions for Akari Therapeutics. Telomir Pharmaceuticals' average media sentiment score of 1.61 beat Akari Therapeutics' score of 0.61 indicating that Telomir Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akari Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Telomir Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has higher valuation & earnings, CRDF or AKTX?

Akari Therapeutics has lower revenue, but higher earnings than Cardiff Oncology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cardiff Oncology $508K 117.20 -$45.85M -$0.60 N/A Akari Therapeutics N/A N/A -$17.30M N/A N/A

Does the media prefer CRDF or AKTX?

In the previous week, Cardiff Oncology and Cardiff Oncology both had 2 articles in the media. Cardiff Oncology's average media sentiment score of 1.56 beat Akari Therapeutics' score of 0.61 indicating that Cardiff Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiff Oncology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Akari Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend KVAC or AKTX?

Akari Therapeutics has a consensus price target of $32.33, indicating a potential upside of 334.00%. Given Akari Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Akari Therapeutics is more favorable than Keen Vision Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Keen Vision Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Akari Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80

Which has better earnings and valuation, KVAC or AKTX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Keen Vision Acquisition N/A N/A N/A N/A N/A Akari Therapeutics N/A N/A -$17.30M N/A N/A

Is KVAC or AKTX more profitable?

Keen Vision Acquisition's return on equity of 0.00% beat Akari Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Keen Vision Acquisition N/A N/A N/A Akari Therapeutics N/A -147.45% -74.70%

Do analysts rate AKTX or APLM?

Akari Therapeutics presently has a consensus target price of $32.33, suggesting a potential upside of 334.00%. Given Akari Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Akari Therapeutics is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akari Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, AKTX or APLM?

Apollomics has higher revenue and earnings than Akari Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Akari Therapeutics N/A N/A -$17.30M N/A N/A Apollomics $8.50M 6.20 -$10.94M N/A N/A

Is AKTX or APLM more profitable?

Apollomics' return on equity of 0.00% beat Akari Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Akari Therapeutics N/A -147.45% -74.70% Apollomics N/A N/A N/A

Does the media favor AKTX or APLM?

In the previous week, Akari Therapeutics and Akari Therapeutics both had 2 articles in the media. Apollomics' average media sentiment score of 0.91 beat Akari Therapeutics' score of 0.61 indicating that Apollomics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akari Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Apollomics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Akari Therapeutics (AKTX) Competitors

$7.45 +0.32 (+4.49%)

Closing price 11/11/2026 04:00 PM Eastern

Extended Trading

$7.46 +0.01 (+0.20%)

As of 11/11/2026 07:56 PM Eastern

Compare

AKTX vs. ACRV, TELO, CRDF, KVAC, and APLM

Should you buy Akari Therapeutics stock or one of its competitors? Akari Therapeutics's main competitors and comparable companies include Acrivon Therapeutics (ACRV), Telomir Pharmaceuticals (TELO), Cardiff Oncology (CRDF), Keen Vision Acquisition (KVAC), and Apollomics (APLM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Akari Therapeutics compare to Acrivon Therapeutics?

Acrivon Therapeutics (NASDAQ:ACRV) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends, profitability and media sentiment.

Acrivon Therapeutics' return on equity of -70.14% beat Akari Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acrivon Therapeutics	N/A	-70.14%	-61.60%
Akari Therapeutics	N/A	-147.45%	-74.70%

Acrivon Therapeutics presently has a consensus price target of $13.50, suggesting a potential upside of 759.87%. Akari Therapeutics has a consensus price target of $32.33, suggesting a potential upside of 334.00%. Given Acrivon Therapeutics' higher probable upside, equities analysts clearly believe Acrivon Therapeutics is more favorable than Akari Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Akari Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

71.6% of Acrivon Therapeutics shares are held by institutional investors. Comparatively, 5.1% of Akari Therapeutics shares are held by institutional investors. 10.5% of Acrivon Therapeutics shares are held by company insiders. Comparatively, 30.0% of Akari Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$1.88	N/A
Akari Therapeutics	N/A	N/A	-$17.30M	N/A	N/A

In the previous week, Acrivon Therapeutics had 6 more articles in the media than Akari Therapeutics. MarketBeat recorded 8 mentions for Acrivon Therapeutics and 2 mentions for Akari Therapeutics. Akari Therapeutics' average media sentiment score of 0.61 beat Acrivon Therapeutics' score of 0.26 indicating that Akari Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acrivon Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Akari Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Acrivon Therapeutics has a beta of 1.96, indicating that its share price is 96% more volatile than the broader market. Comparatively, Akari Therapeutics has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market.

Summary

Acrivon Therapeutics beats Akari Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Akari Therapeutics compare to Telomir Pharmaceuticals?

Akari Therapeutics (NASDAQ:AKTX) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.

Akari Therapeutics has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market. Comparatively, Telomir Pharmaceuticals has a beta of -0.19, meaning that its share price is 119% less volatile than the broader market.

In the previous week, Telomir Pharmaceuticals had 1 more articles in the media than Akari Therapeutics. MarketBeat recorded 3 mentions for Telomir Pharmaceuticals and 2 mentions for Akari Therapeutics. Telomir Pharmaceuticals' average media sentiment score of 1.61 beat Akari Therapeutics' score of 0.61 indicating that Telomir Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Akari Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Telomir Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Akari Therapeutics presently has a consensus target price of $32.33, indicating a potential upside of 334.00%. Telomir Pharmaceuticals has a consensus target price of $4.00, indicating a potential upside of 572.27%. Given Telomir Pharmaceuticals' higher probable upside, analysts plainly believe Telomir Pharmaceuticals is more favorable than Akari Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akari Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akari Therapeutics	N/A	N/A	-$17.30M	N/A	N/A
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.89	N/A

Telomir Pharmaceuticals' return on equity of -107.89% beat Akari Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akari Therapeutics	N/A	-147.45%	-74.70%
Telomir Pharmaceuticals	N/A	-107.89%	-94.72%

5.1% of Akari Therapeutics shares are owned by institutional investors. 30.0% of Akari Therapeutics shares are owned by company insiders. Comparatively, 16.4% of Telomir Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Akari Therapeutics beats Telomir Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does Akari Therapeutics compare to Cardiff Oncology?

Cardiff Oncology (NASDAQ:CRDF) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, institutional ownership and risk.

Cardiff Oncology has a beta of 1.57, suggesting that its share price is 57% more volatile than the broader market. Comparatively, Akari Therapeutics has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market.

In the previous week, Cardiff Oncology and Cardiff Oncology both had 2 articles in the media. Cardiff Oncology's average media sentiment score of 1.56 beat Akari Therapeutics' score of 0.61 indicating that Cardiff Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiff Oncology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Akari Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

16.3% of Cardiff Oncology shares are held by institutional investors. Comparatively, 5.1% of Akari Therapeutics shares are held by institutional investors. 8.8% of Cardiff Oncology shares are held by company insiders. Comparatively, 30.0% of Akari Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Akari Therapeutics has lower revenue, but higher earnings than Cardiff Oncology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiff Oncology	$508K	117.20	-$45.85M	-$0.60	N/A
Akari Therapeutics	N/A	N/A	-$17.30M	N/A	N/A

Akari Therapeutics has a net margin of 0.00% compared to Cardiff Oncology's net margin of -7,885.43%. Cardiff Oncology's return on equity of -103.10% beat Akari Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiff Oncology	-7,885.43%	-103.10%	-75.52%
Akari Therapeutics	N/A	-147.45%	-74.70%

Cardiff Oncology currently has a consensus target price of $7.50, suggesting a potential upside of 880.01%. Akari Therapeutics has a consensus target price of $32.33, suggesting a potential upside of 334.00%. Given Cardiff Oncology's higher possible upside, research analysts clearly believe Cardiff Oncology is more favorable than Akari Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiff Oncology	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Akari Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

Cardiff Oncology and Akari Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Akari Therapeutics compare to Keen Vision Acquisition?

Keen Vision Acquisition (NASDAQ:KVAC) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends.

Keen Vision Acquisition has a beta of -0.04, suggesting that its stock price is 104% less volatile than the broader market. Comparatively, Akari Therapeutics has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Keen Vision Acquisition	N/A	N/A	N/A	N/A	N/A
Akari Therapeutics	N/A	N/A	-$17.30M	N/A	N/A

In the previous week, Akari Therapeutics had 2 more articles in the media than Keen Vision Acquisition. MarketBeat recorded 2 mentions for Akari Therapeutics and 0 mentions for Keen Vision Acquisition. Akari Therapeutics' average media sentiment score of 0.61 beat Keen Vision Acquisition's score of 0.00 indicating that Akari Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Keen Vision Acquisition	Neutral
Akari Therapeutics	Positive

Akari Therapeutics has a consensus price target of $32.33, indicating a potential upside of 334.00%. Given Akari Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Akari Therapeutics is more favorable than Keen Vision Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Keen Vision Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Akari Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

51.7% of Keen Vision Acquisition shares are owned by institutional investors. Comparatively, 5.1% of Akari Therapeutics shares are owned by institutional investors. 80.2% of Keen Vision Acquisition shares are owned by insiders. Comparatively, 30.0% of Akari Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Keen Vision Acquisition's return on equity of 0.00% beat Akari Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Keen Vision Acquisition	N/A	N/A	N/A
Akari Therapeutics	N/A	-147.45%	-74.70%

Summary

Akari Therapeutics beats Keen Vision Acquisition on 7 of the 11 factors compared between the two stocks.

How does Akari Therapeutics compare to Apollomics?

Akari Therapeutics (NASDAQ:AKTX) and Apollomics (NASDAQ:APLM) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, media sentiment, analyst recommendations and institutional ownership.

In the previous week, Akari Therapeutics and Akari Therapeutics both had 2 articles in the media. Apollomics' average media sentiment score of 0.91 beat Akari Therapeutics' score of 0.61 indicating that Apollomics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Akari Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Apollomics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

5.1% of Akari Therapeutics shares are held by institutional investors. Comparatively, 19.1% of Apollomics shares are held by institutional investors. 30.0% of Akari Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Apollomics has higher revenue and earnings than Akari Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akari Therapeutics	N/A	N/A	-$17.30M	N/A	N/A
Apollomics	$8.50M	6.20	-$10.94M	N/A	N/A

Akari Therapeutics has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market. Comparatively, Apollomics has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market.

Akari Therapeutics presently has a consensus target price of $32.33, suggesting a potential upside of 334.00%. Given Akari Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Akari Therapeutics is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akari Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Apollomics' return on equity of 0.00% beat Akari Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akari Therapeutics	N/A	-147.45%	-74.70%
Apollomics	N/A	N/A	N/A

Summary

Apollomics beats Akari Therapeutics on 7 of the 12 factors compared between the two stocks.

Get Akari Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AKTX vs. The Competition

Export

Metric	Akari Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$16.29M	$4.15B	$7.89B	$12.02B
Dividend Yield	N/A	3.63%	2.45%	4.45%
P/E Ratio	N/A	26.31	33.34	29.15
Price / Sales	N/A	16.44	8.76	5.83
Price / Cash	N/A	26.63	22.08	22.50
Price / Book	0.30	4.22	4.45	3.80
Net Income	-$17.30M	-$22.76M	$3.50B	$390.04M
7 Day Performance	-3.87%	3.90%	2.56%	3.40%
1 Month Performance	-12.76%	-5.16%	-3.18%	-5.35%
1 Year Performance	-65.69%	-0.70%	1.04%	-5.92%

Akari Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AKTX Akari Therapeutics	3.0055 of 5 stars	$7.45 +4.5%	$32.33 +334.0%	-68.5%	$16.29M	N/A	N/A	6
ACRV Acrivon Therapeutics	3.0558 of 5 stars	$1.67 +3.7%	$13.50 +708.4%	-24.2%	$68.99M	N/A	N/A	76	Analyst Forecast
TELO Telomir Pharmaceuticals	2.191 of 5 stars	$0.91 -0.6%	$4.00 +339.6%	-58.1%	$67.42M	N/A	N/A	5	Positive News Earnings Report Gap Up
CRDF Cardiff Oncology	1.9753 of 5 stars	$0.86 +2.2%	$7.50 +769.0%	-66.6%	$65.68M	$590K	N/A	31	Positive News Analyst Upgrade
KVAC Keen Vision Acquisition	N/A	$11.51 flat	N/A	N/A	$63.37M	N/A	N/A	N/A	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AKTX) was last updated on 11/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Akari Therapeutics (AKTX) Competitors

AKTX vs. ACRV, TELO, CRDF, KVAC, and APLM

How does Akari Therapeutics compare to Acrivon Therapeutics?

Summary

How does Akari Therapeutics compare to Telomir Pharmaceuticals?

Summary

How does Akari Therapeutics compare to Cardiff Oncology?

Summary

How does Akari Therapeutics compare to Keen Vision Acquisition?

Summary

How does Akari Therapeutics compare to Apollomics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKTX vs. The Competition

Akari Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Akari Therapeutics (AKTX) Competitors

AKTX vs. ACRV, TELO, CRDF, KVAC, and APLM

How does Akari Therapeutics compare to Acrivon Therapeutics?

Is ACRV or AKTX more profitable?

Do analysts prefer ACRV or AKTX?

Do insiders and institutionals believe in ACRV or AKTX?

Which has preferable earnings & valuation, ACRV or AKTX?

Does the media prefer ACRV or AKTX?

Which has more risk and volatility, ACRV or AKTX?

Summary

How does Akari Therapeutics compare to Telomir Pharmaceuticals?

Which has more risk and volatility, AKTX or TELO?

Does the media favor AKTX or TELO?

Do analysts recommend AKTX or TELO?

Which has better earnings & valuation, AKTX or TELO?

Is AKTX or TELO more profitable?

Do institutionals & insiders believe in AKTX or TELO?

Summary

How does Akari Therapeutics compare to Cardiff Oncology?

Which has more volatility & risk, CRDF or AKTX?

Does the media prefer CRDF or AKTX?

Do insiders and institutionals hold more shares of CRDF or AKTX?

Which has higher valuation & earnings, CRDF or AKTX?

Is CRDF or AKTX more profitable?

Do analysts recommend CRDF or AKTX?

Summary

How does Akari Therapeutics compare to Keen Vision Acquisition?

Which has more risk & volatility, KVAC or AKTX?

Which has better earnings and valuation, KVAC or AKTX?

Does the media prefer KVAC or AKTX?

Do analysts recommend KVAC or AKTX?

Do insiders and institutionals have more ownership in KVAC or AKTX?

Is KVAC or AKTX more profitable?

Summary

How does Akari Therapeutics compare to Apollomics?

Does the media favor AKTX or APLM?

Do insiders & institutionals have more ownership in AKTX or APLM?

Which has preferable earnings and valuation, AKTX or APLM?

Which has more volatility and risk, AKTX or APLM?

Do analysts rate AKTX or APLM?

Is AKTX or APLM more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKTX vs. The Competition

Akari Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools